Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 3, 2010, Pages 763-772

  Deville, Curtiland ^a   Both, Stefan ^a   Hwang, Wei Ting ^a   Tochner, Zelig ^a   Vapiwala, Neha ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

IMRT; Pelvic nodal irradiation; Prostate cancer; Toxicity; Whole pelvis

Indexed keywords

ANDROGEN DEPRIVATION; COMPUTED TOMOGRAPHY; DOSE-VOLUME HISTOGRAMS; DOSIMETRIC PARAMETER; FISHER EXACT TEST; IMRT; INTENSITY MODULATED RADIATION THERAPY; KAPLAN-MEIER; LOW DOSE; MEAN DOSE; P-VALUES; PELVIC NODAL IRRADIATION; PROSTATE CANCERS; RADIATION THERAPY ONCOLOGY GROUPS; SURVIVAL CURVES; T-TESTS; TREATMENT PLANNING; WHOLE PELVIS;

COMPUTERIZED TOMOGRAPHY; DISEASES; DOSIMETERS; DOSIMETRY; IRRADIATION; PHYSICAL THERAPY; RADIOTHERAPY;

TOXICITY;

ANTIANDROGEN;

AGED; ARTICLE; BLADDER; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HISTOGRAM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; INTESTINE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PELVIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RECTUM; RETROSPECTIVE STUDY; SIMULATION; TREATMENT PLANNING; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; GASTROINTESTINAL TRACT; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; RADIOTHERAPY; RISK; TUMOR VOLUME; UROGENITAL SYSTEM;

AGED; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; GASTROINTESTINAL TRACT; HUMANS; LYMPHATIC IRRADIATION; MALE; PELVIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; RETROSPECTIVE STUDIES; RISK; TUMOR BURDEN; URINARY BLADDER; UROGENITAL SYSTEM;

EID: 77957204585     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.08.043     Document Type: Article

References (39)

1. M. Roach III, M. DeSilvio, and C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911 (Pubitemid 46606377)
2. C.A. Lawton, M. DeSilvio, and M. Roach III An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655
3. P. Pommier, S. Chabaud, and J.L. Lagrange Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01 J Clin Oncol 25 2007 5366 5373
4. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
5. G.E. Hanks, T.F. Pajak, and A. Porter Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
6. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
7. A. Pollack A call for more with a desire for less (pelvic radiotherapy with androgen deprivation in the treatment of prostate cancer) J Clin Oncol 21 2003 1899 1901
8. R.D. Ennis Uncertainties regarding pelvic radiotherapy for prostate cancer J Clin Oncol 22 2004 2254 2255
9. M. Roach In reply [Letter] J Clin Oncol 22 2004 2255 2257
10. M.J. Zelefsky, Z. Fuks, and M. Hunt High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients Int J Radiat Oncol Biol Phys 53 2002 1111 1116
11. H.A. Shih, M. Harisinghani, and A.L. Zietman Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy Int J Radiat Oncol Biol Phys 63 2005 1262 1269
12. G. Sanguineti, E.J. Endres, and B.C. Parker Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer Acta Oncol 47 2008 301 310
13. A.W. Su, and A.B. Jani Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique Am J Clin Oncol 30 2007 215 219
14. J.B. Ashman, M.J. Zelefsky, M.S. Hunt, S.A. Leibel, and Z. Fuks Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy Int J Radiat Oncol Biol Phys 63 2005 765 771
15. G. Sanguineti, M.L. Cavey, and E.J. Endres Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy? Strahlenther Onkol 182 2006 543 549
16. M. Guckenberger, K. Baier, A. Richter, D. Vordermark, and M. Flentje Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to the treatment of the prostate only? Radiother Oncol 3 2008 3
17. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
18. M. Roach The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 1923 1924
19. J.H. Yoon, M.H. Chen, A.A. Renshaw, J.P. Richie, and A.V. D'Amico Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer J Urol 60 2002 454 457
20. J.K. Ryu, K. Winter, and J.M. Michalski Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy) Int J Radiat Oncol Biol Phys 54 2002 1036 1046
21. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
22. M.R. Cheung, S.L. Tucker, and L. Dong Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 67 2007 1059 1065
23. S.T. Peeters, M.S. Hoogeman, and W.D. Heemsbergen Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 63 2005 1142 1152
24. A. Karlsdottir, D.C. Johannessen, L.P. Muren, T. Wentzel-Larsen, and O. Dahl Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer Radiother Oncol 71 2004 43 53
25. W.R. Lee, G.E. Hanks, A.L. Hanlon, T.E. Schultheiss, and M.A. Hunt Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect Int J Radiat Oncol Biol Phys 35 1996 251 257
26. A. Jackson, M.W. Skwarchuk, and M.J. Zelefsky Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms Int J Radiat Oncol Biol Phys 49 2001 685 698
27. C. Greco, C. Mazzetta, and F. Cattani Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer Radiother Oncol 69 2003 215 222
28. W.D. Heemsbergen, M.S. Hoogeman, G.A. Hart, J.V. Lebesque, and P.C. Koper Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy Int J Radiat Oncol Biol Phys 61 2005 1011 1018
29. C. Fiorino, G. Sanguineti, and C. Cozzarini Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer Int J Radiat Oncol Biol Phys 57 2003 953 962
30. M.R. Storey, A. Pollack, and G. Zagars Complications from radiotherapy dose escalation in prostate cancer. preliminary results of a randomized trial Int J Radiat Oncol Biol Phys 48 2000 635 642
31. M. Roach, M. DeSilvio, and R. Valicenti Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial Int J Radiat Oncol Biol Phys 66 2006 647 653
32. C.A. Lawton, K. Bae, M. Pilepich, G. Hanks, and W. Shipley Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: Analysis of Radiation Therapy Oncology Group studies 85-31, 86-10, and 92-02 Int J Radiat Oncol Biol Phys 70 2008 437 441
33. S. Arcangeli, B. Saracino, and M.G. Petrongari Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area Radiother Oncol 84 2007 148 155
34. P. Ghadjar, J. Vock, and D. Vetterli Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking Radiat Oncol 3 2008 35
35. V. Fonteyne, G. Villeirs, N. Lumen, and G. De Meerleer Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer Radiother Oncol 92 2009 42 47
36. H.T. Chung, P. Xia, L.W. Chan, E. Park-Somers, and M. Roach III Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT Int J Radiat Oncol Biol Phys 73 2009 53 60
37. G. De Meerleer, L. Vakaet, and S. Meersschout Intensity-modulated radiotherapy as primary treatment for prostate cancer: Acute toxicity in 114 patients Int J Radiat Oncol Biol Phys 60 2004 777 787
38. C.A. Lawton, J. Michalski, and I. El-Naqa RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer Int J Radiat Oncol Biol Phys 74 2009 383 387
39. S.J. Feigenberg, A.L. Hanlon, and E.M. Horwitz Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy Int J Radiat Oncol Biol Phys 62 2005 397 405